Who Paid My Doc
AMAG Pharmaceuticals, Inc.
MA, United States
CMS manufacturer 100000010948
General payments
$3,337,635
Research payments
$6,992,966
Ownership & investment interest
$0
Through program year 2024, AMAG Pharmaceuticals, Inc. reported paying $3,337,635 in general payments and $6,992,966 in research payments to U.S. physicians, teaching hospitals and other recipients.
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | General | $48,927 | 8 |
| 2024 | Research | $278,852 | 53 |
| 2023 | General | $97,920 | 28 |
| 2023 | Research | $572,116 | 84 |
| 2022 | General | $299,599 | 904 |
| 2022 | Research | $532,005 | 60 |
| 2021 | General | $252,900 | 2,481 |
| 2021 | Research | $570,382 | 85 |
| 2020 | General | $904,984 | 3,157 |
| 2020 | Research | $631,826 | 171 |
| 2019 | General | $1,733,305 | 18,875 |
| 2019 | Research | $4,407,784 | 858 |
Breakdown
Each share is of this company’s general payments naming a product in 2024. A payment can name up to five products, so these amounts overlap.
Each share is of this company’s general payments to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.
Each share is of this company’s general payments in 2024 where a state was reported.
Records
25,453 general · 1,311 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.